Switch theme
Sign up to access all valuation multiples
Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug addresses serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment in the PRC which is pharmaceutical manufacturing.
1992
9.1K+
LTM Revenue $1.7B
LTM EBITDA $447M
$3.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Livzon Pharmaceutical Gr has a last 12-month revenue (LTM) of $1.7B and a last 12-month EBITDA of $447M.
In the most recent fiscal year, Livzon Pharmaceutical Gr achieved revenue of $1.6B and an EBITDA of $482M.
Livzon Pharmaceutical Gr expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Livzon Pharmaceutical Gr valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $447M | XXX | $482M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $395M | XXX | $393M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $297M | XXX | $286M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Livzon Pharmaceutical Gr's stock price is CNY 33 (or $5).
Livzon Pharmaceutical Gr has current market cap of CNY 30.0B (or $4.2B), and EV of CNY 23.0B (or $3.2B).
See Livzon Pharmaceutical Gr trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.2B | $4.2B | XXX | XXX | XXX | XXX | $0.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Livzon Pharmaceutical Gr has market cap of $4.2B and EV of $3.2B.
Livzon Pharmaceutical Gr's trades at 1.9x EV/Revenue multiple, and 6.6x EV/EBITDA.
Equity research analysts estimate Livzon Pharmaceutical Gr's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Livzon Pharmaceutical Gr has a P/E ratio of 14.0x.
See valuation multiples for Livzon Pharmaceutical Gr and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.2B | XXX | $4.2B | XXX | XXX | XXX |
| EV (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 7.1x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBIT | 8.1x | XXX | 8.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.0x | XXX | 14.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 9.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLivzon Pharmaceutical Gr's last 12 month revenue growth is 4%
Livzon Pharmaceutical Gr's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Livzon Pharmaceutical Gr's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Livzon Pharmaceutical Gr's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Livzon Pharmaceutical Gr and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | -2% | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Livzon Pharmaceutical Gr acquired XXX companies to date.
Last acquisition by Livzon Pharmaceutical Gr was XXXXXXXX, XXXXX XXXXX XXXXXX . Livzon Pharmaceutical Gr acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Livzon Pharmaceutical Gr founded? | Livzon Pharmaceutical Gr was founded in 1992. |
| Where is Livzon Pharmaceutical Gr headquartered? | Livzon Pharmaceutical Gr is headquartered in China. |
| How many employees does Livzon Pharmaceutical Gr have? | As of today, Livzon Pharmaceutical Gr has 9.1K+ employees. |
| Is Livzon Pharmaceutical Gr publicy listed? | Yes, Livzon Pharmaceutical Gr is a public company listed on SHE. |
| What is the stock symbol of Livzon Pharmaceutical Gr? | Livzon Pharmaceutical Gr trades under 000513 ticker. |
| When did Livzon Pharmaceutical Gr go public? | Livzon Pharmaceutical Gr went public in 1993. |
| Who are competitors of Livzon Pharmaceutical Gr? | Similar companies to Livzon Pharmaceutical Gr include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Livzon Pharmaceutical Gr? | Livzon Pharmaceutical Gr's current market cap is $4.2B |
| What is the current revenue of Livzon Pharmaceutical Gr? | Livzon Pharmaceutical Gr's last 12 months revenue is $1.7B. |
| What is the current revenue growth of Livzon Pharmaceutical Gr? | Livzon Pharmaceutical Gr revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Livzon Pharmaceutical Gr? | Current revenue multiple of Livzon Pharmaceutical Gr is 1.9x. |
| Is Livzon Pharmaceutical Gr profitable? | Yes, Livzon Pharmaceutical Gr is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Livzon Pharmaceutical Gr? | Livzon Pharmaceutical Gr's last 12 months EBITDA is $447M. |
| What is Livzon Pharmaceutical Gr's EBITDA margin? | Livzon Pharmaceutical Gr's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Livzon Pharmaceutical Gr? | Current EBITDA multiple of Livzon Pharmaceutical Gr is 7.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
